Christelle Remy-Ziller, et al. Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article Publication
Category: 2017
Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
20171012 PR TG4010 publications
Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
20171002-PR-TG-Randox-final
Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
20170905 Invirio PR US
First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
170919-Transgene-FPI-Announcement_US
First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
20170913 EN – CP Resultats financiers final
Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
20170907-ESMO-Metromajx-poster-EN
A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8 Download the poster here Poster Presentation
Transgene Announces Upcoming Investor Meetings
TNG-PR-financial-agenda-H217-EN
